Sarepta rises after Mizuho upgrades rating, lifts PT on Elevidys adoption

Shares of genetic medicine maker Sarepta Therapeutics SRPT.O rise 2.4% to $16.59 premarket, after Mizuho upgrades stock to "outperform" from "neutral"

The brokerage raises SRPT's price target to $26 from $19

"We have higher confidence in Elevidys adoption, given the strong demand leading to 3Q25 outperformance," says Mizuho

SRPT shares had plunged 30% on Tuesday after a weak forecast for its top-selling gene therapy Elevidys and failure of two of its approved drugs in a key trial

Eight of 29 brokerages rate the stock "buy" or higher, 16 "hold" and 5 "sell" or lower; their median PT is $18, according to LSEG data

Up to last close, stock is down 86.7% YTD, its biggest yearly drop ever vs 21.7% gain for NASDAQ Biotechnology Index .NBI